Impact Partnership Wealth’s BioAtla BCAB Stock Holding History

Impact Partnership Wealth’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3	Closed	-$387	–	1019
2023 Q2	$387	Buy	+3	New	+$516	﹤0.01%	870

Other funds holding BCAB

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Impact Partnership Wealth's BCAB Position: Q3 2023 in Review

Impact Partnership Wealth sold out of BioAtla (BCAB) in Q3 2023, closing a stake of 3 shares — an estimated $387 sold.

Impact Partnership Wealth first reported a position in BCAB in Q2 2023 and held it in 1 quarter. The position peaked at $387 in Q2 2023. 82 funds tracked by Wall St. Rank hold BCAB as of Q3 2023.

Impact Partnership Wealth reported no remaining BioAtla position as of Q3 2023 after selling out during the quarter.
Impact Partnership Wealth sold 3 BioAtla shares in Q3 2023, an estimated $387.
Impact Partnership Wealth first reported a position in BioAtla in Q2 2023 and held it in 1 quarter.
Impact Partnership Wealth's BioAtla position peaked at $387 in Q2 2023.
82 funds tracked by Wall St. Rank held BioAtla as of Q3 2023.

Based on Impact Partnership Wealth's 13F filing for Q3 2023, filed 17 Oct 2023.